Humanigen, Inc. Settlement

Claim Deadline: March 07, 2024 · Settlement Fund: $3,000,000 · Settlement Class · Important Documents.

Pomerantz Appointed Co-Lead Counsel in Humanigen

This securities action alleges that Humanigen, Inc. (“Humanigen” or the “Company”) misled the market regarding the regulatory and commercial prospects for

Securities Fraud Claims on Behalf of Humanigen, Inc.

The law firm of Edelson Lechtzin LLP is investigating securities fraud claims on behalf of all purchasers of Humanigen, Inc. (Humanigen or the Company) (NASDAQ

In re Humanigen Sec. Litig., 2:22-cv-05258 (WJM)

Plaintiffs allege that between May 16, 2020, and July 12, 2022, Defendants made a series of false and/or materially misleading statements.

humanigen inc securities settlement

The purpose of this website is to advise members of the Settlement Class of the Settlement of the Action entitled In re Humanigen, Inc. Securities

HUMANIGEN, INC. (NASDAQ:HGEN) SHAREHOLDER

The lawsuit was filed in the United States District Court for the District of New Jersey and alleges violations of the Securities Exchange Act of 1934.

突出特色

快速

體驗快速反應和高效能

安全

保證資料安全和隱私保護

智能

智能功能帶來便捷體驗

humanigen securities litigation - Drugmaker Accused of Overhyping Proposed COVID